Skip to Main Content

Author Details

Christopher E Barbieri
Weill Cornell Medical College
2003
111
37
PMIDPaper TitleJournal TitlePublished Year
36727462SMAD3 promotes expression and activity of the androgen receptor in prostate cancer.Nucleic Acids Res2023
37608258Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER).BMC Cancer2023
37581614SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression.Clin Cancer Res2023
37301735Prostate cancer genetic alterations in Hispanic men.Prostate2023
37236832Impact of Magnetic Resonance Imaging Targeting on Pathologic Upgrading and Downgrading at Prostatectomy: A Systematic Review and Meta-analysis.Eur Urol Oncol2023
36727462SMAD3 promotes expression and activity of the androgen receptor in prostate cancer.Nucleic Acids Res2023
37034687Distinct mesenchymal cell states mediate prostate cancer progression.bioRxiv2023
37581614SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression.Clin Cancer Res2023
37608258Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER).BMC Cancer2023
37236832Impact of Magnetic Resonance Imaging Targeting on Pathologic Upgrading and Downgrading at Prostatectomy: A Systematic Review and Meta-analysis.Eur Urol Oncol2023
37301735Prostate cancer genetic alterations in Hispanic men.Prostate2023
37034687Distinct mesenchymal cell states mediate prostate cancer progression.bioRxiv2023
35050902Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.JCI Insight2022
35900150Impact of Left-Digit Age Bias in the Treatment of Localized Prostate Cancer.J Urol2022
35945369Race and prostate cancer: genomic landscape.Nat Rev Urol2022
35814856Trends in Androgen Deprivation Use in Men With Intermediate-Risk Prostate Cancer Who Underwent Radiation Therapy.Adv Radiat Oncol2022
35637420Identifying synergistic high-order 3D chromatin conformations from genome-scale nanopore concatemer sequencing.Nat Biotechnol2022
35490048A multidisciplinary approach to optimize primary prostate cancer biobanking.Urol Oncol2022
36138136JAK inhibition shows two faces in prostate cancer.Nat Cancer2022
35721307Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men.NEJM Evid2022
34999736Elevated expression of the colony-stimulating factor 1 (CSF1) induces prostatic intraepithelial neoplasia dependent of epithelial-Gp130.Oncogene2022
35050902Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.JCI Insight2022
35637420Identifying synergistic high-order 3D chromatin conformations from genome-scale nanopore concatemer sequencing.Nat Biotechnol2022
35721307Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men.NEJM Evid2022
35490048A multidisciplinary approach to optimize primary prostate cancer biobanking.Urol Oncol2022
35814856Trends in Androgen Deprivation Use in Men With Intermediate-Risk Prostate Cancer Who Underwent Radiation Therapy.Adv Radiat Oncol2022
36138136JAK inhibition shows two faces in prostate cancer.Nat Cancer2022
35900150Impact of Left-Digit Age Bias in the Treatment of Localized Prostate Cancer.J Urol2022
35945369Race and prostate cancer: genomic landscape.Nat Rev Urol2022
34999736Elevated expression of the colony-stimulating factor 1 (CSF1) induces prostatic intraepithelial neoplasia dependent of epithelial-Gp130.Oncogene2022
32385798Patient injuries and malfunctions associated with robotic prostatectomy: review of the manufacturer and user facility device experience database.J Robot Surg2021
35755405Three-dimensional prostate CT segmentation through fine-tuning of a pre-trained neural network using no reference labeling.Proc SPIE Int Soc Opt Eng2021
32385798Patient injuries and malfunctions associated with robotic prostatectomy: review of the manufacturer and user facility device experience database.J Robot Surg2021
34123846Tissue-Based Biomarkers for the Risk Stratification of Men With Clinically Localized Prostate Cancer.Front Oncol2021
33998599Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer.J Clin Invest2021
33563537Tumor size and genomic risk in localized prostate cancer.Urol Oncol2021
34091024Re: Early Results of Unilateral Prostatic Artery Embolization as a Focal Therapy in Patients with Prostate Cancer under Active Surveillance: Cancer Prostate Embolization, a Pilot Study.J Vasc Interv Radiol2021
33502239Understanding the True Prevalence of Prostate Cancer Genomic Subtypes: Use of Inverse Probability Weighting to Correct for Biases in Molecularly Profiled Cohorts.J Urol2021
32658588Active Surveillance for Men with Intermediate Risk Prostate Cancer.J Urol2021
34746633Race and Genetic Alterations in Prostate Cancer.JCO Precis Oncol2021
34795264G3BP1 inhibits Cul3<sup>SPOP</sup> to amplify AR signaling and promote prostate cancer.Nat Commun2021
34503356Editorial Comment.J Urol2021
34496233Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity.Cell Rep2021
35755405Three-dimensional prostate CT segmentation through fine-tuning of a pre-trained neural network using no reference labeling.Proc SPIE Int Soc Opt Eng2021
33563537Tumor size and genomic risk in localized prostate cancer.Urol Oncol2021
33502239Understanding the True Prevalence of Prostate Cancer Genomic Subtypes: Use of Inverse Probability Weighting to Correct for Biases in Molecularly Profiled Cohorts.J Urol2021
34496233Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity.Cell Rep2021
34746633Race and Genetic Alterations in Prostate Cancer.JCO Precis Oncol2021
34795264G3BP1 inhibits Cul3<sup>SPOP</sup> to amplify AR signaling and promote prostate cancer.Nat Commun2021
34503356Editorial Comment.J Urol2021
  • 1 - 50 of 222

Recommended Authors

Michael Sigouros
Caryl and Israel Englander Institute for Precision Medicine
Career Start Year 2017
Number of shared co-authors 47
Travis Gerke
The Prostate Cancer Clinical Trials Consortium
Career Start Year 2014
Number of shared co-authors 26
Julie Livingstone
University of California los angeles
Career Start Year 2011
Number of shared co-authors 13
Adam G Sowalsky
National Cancer Institute
Career Start Year 2010
Number of shared co-authors 22
Alexander W Wyatt
University of British Columbia
Career Start Year 2007
Number of shared co-authors 34
Mark M Pomerantz
Dana-Farber Cancer Institute
Career Start Year 2007
Number of shared co-authors 33
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 9
Mitchell G Lawrence
Biomedicine Discovery Institute, Monash University
Career Start Year 2005
Number of shared co-authors 3
Robert H Bell
University of British Columbia
Career Start Year 2004
Number of shared co-authors 14
Thorsten Schlomm
Charite - University Hospital Berlin
Career Start Year 2004
Number of shared co-authors 15
Anne Y Warren
Cambridge University Hospitals National Health Service Foundation Trust
Career Start Year 2003
Number of shared co-authors 7
Ashley E Ross
Northwestern University
Career Start Year 2003
Number of shared co-authors 35
Adam Foye
University of California San Francisco
Career Start Year 2003
Number of shared co-authors 20
Heather H Cheng
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 2002
Number of shared co-authors 54
Tarek A Bismar
University of Calgary Cumming School of Medicine, Rockyview General Hospital
Career Start Year 2002
Number of shared co-authors 34
Michael Fraser
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2001
Number of shared co-authors 15
Yuzhuo Wang
University of British Columbia
Career Start Year 2000
Number of shared co-authors 53
Rohit Mehra
Michigan Center for Translational Pathology.
Career Start Year 2000
Number of shared co-authors 69
Srinivasan Yegnasubramanian
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 27
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 33
Hayley C Whitaker
University College London
Career Start Year 1999
Number of shared co-authors 6
Xuhong Cao
Michigan Center for Translational Pathology.
Career Start Year 1999
Number of shared co-authors 50
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 24
Ganesh V Raj
University of Texas Southwestern Medical Center at Dallas
Career Start Year 1994
Number of shared co-authors 25
Isla P Garraway
David Geffen School of Medicine University of California Los Angeles
Career Start Year 1993
Number of shared co-authors 23
Rosina T Lis
National Cancer Institute
Career Start Year 1992
Number of shared co-authors 57
Marshall Scott Lucia
University of Colorado School of Medicine
Career Start Year 1991
Number of shared co-authors 6
Gyorgy Petrovics
Henry Jackson Foundation for the Advancement of Military Medicine (HJF)
Career Start Year 1990
Number of shared co-authors 16
George Steven Bova
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 1982
Number of shared co-authors 8
William B Isaacs
The Brady Urological Institute, The Johns Hopkins School of Medicine
Career Start Year 1979
Number of shared co-authors 34

Collaborators

Mark A Rubin
University of Bern
Co-authored papers 35
Andrea Sboner
Institute for Computational Biomedicine
Co-authored papers 23
Brian D Robinson
Sandra and Edward Meyer Cancer Center
Co-authored papers 19
Juan Miguel Mosquera
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 17
Douglas S Scherr
New York-Presbyterian Hospital
Co-authored papers 16
Francesca Demichelis
University of Trento
Co-authored papers 16
Mirjam Blattner
Co-authored papers 12
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers 10
Kyung Park
New York University Langone Health
Co-authored papers 9
Levi A Garraway
Broad Institute of Harvard and MIT
Co-authored papers 8
Olivier Elemento
Meyer Cancer Center
Co-authored papers 8
Theresa Y MacDonald
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 8
Himanshu Nagar
New York-Presbyterian Hospital, Weill Cornell Medical Center
Co-authored papers 7
Elai Davicioni
Veracyte Inc.
Co-authored papers 7
Davide Prandi
University of Trento
Co-authored papers 6
Jacqueline Fontugne
Institut Curie, CNRS, PSL Research University
Co-authored papers 6
Jim C Hu
Weill Cornell Medical Center
Co-authored papers 6
Arul M Chinnaiyan
University of Michigan Medical School.
Co-authored papers 6
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Co-authored papers 5
Gunther Boysen
Co-authored papers 5
Alessandro Romanel
University of Trento
Co-authored papers 5
Johann S de Bono
The Institute for Cancer Research
Co-authored papers 5
Yang Liu
Veracyte inc.
Co-authored papers 5
Bilal Chughtai
New York Presbyterian Hospital-Weill Cornell
Co-authored papers 5
Ashutosh K Tewari
Co-authored papers 5
David S Rickman
Meyer Cancer Center
Co-authored papers 4
Massimo Loda
Weill Medical College of Cornell University
Co-authored papers 4
Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers 4
Colin C Pritchard
University of Washington, USA Brotman Baty Institute for Precision Medicine
Co-authored papers 4
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 4
Release 1.2